查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602820

抗凝血劑市場：按給藥途徑、抗凝血劑、藥物類別和應用分類 - 2025-2030 年全球預測

Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

據預測，2023年抗凝血藥物市值為402億美元，預計2024年將達到442.4億美元，複合年成長率為10.14%，到2030年將達到790.7億美元。

抗凝血劑是一類預防血栓形成的藥物，血栓形成可能導致中風、心臟病和深層靜脈栓塞症等疾病。抗凝血劑在血栓性疾病的管理和預防中至關重要，因此涵蓋製藥、生物技術和醫療領域。心血管疾病盛行率不斷上升，以及更容易患此類疾病的老年人數量不斷增加，推動了對這些藥物的需求。抗凝血劑的應用遍及醫院、診所和居家醫療，用於治療和預防方案。最終用途範圍主要涉及醫療保健提供者，研究機構和藥品製造商是開發和分銷的主要相關人員。關鍵的成長要素包括藥物輸送系統的進步、對血栓症形成認知的提高以及採用新型口服藥物（NOAC）來取代Warfarin等傳統治療方法。該市場也受到亞太地區新興市場和特異性抗凝血劑等技術創新的推動，提供了利潤豐厚的機會。

主要市場統計
基準年[2023] 402億美元
預測年份 [2024] 442.4億美元
預測年份 [2030] 790.7億美元
複合年成長率（%） 10.14%

然而，市場成長面臨挑戰，例如 NOAC 的高成本、嚴格的法規結構以及需要仔細病患監測的出血併發症的風險。解毒劑的開發仍然是一個重大限制，影響了 NOAC 的廣泛使用。技術創新和研究正在進行中，以開發更安全、更有效、副作用更少的藥物。利用藥物基因學見解進行個人化藥物治療是業務成長的一個有希望的前沿領域。市場競爭激烈，主要企業在研發方面投入大量資金。因此，利用現實世界的資料和人工智慧來改善患者的治療結果為未來的探索提供了一個令人興奮的領域，並最終完善抗凝血劑的治療指標，我們的目標是減少這些問題。

市場動態：揭示快速發展的抗凝血劑市場的關鍵市場洞察

供需的動態交互作用正在改變抗凝血劑市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 靜脈血栓栓塞症和心血管疾病的盛行率增加
    • 增加抗凝血管理計劃
    • 擴大新型口服抗凝血劑的接受度
  • 市場限制因素
    • 關於劑量和臨床核准的嚴格規定
  • 市場機會
    • 採用新的抗凝血治療方法並增加研發投入
    • 利用人工智慧和機器學習預測抗凝血控制
  • 市場問題
    • 與使用口服藥物相關的副作用和併發症

波特五力：駕馭抗凝血藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解抗凝血劑市場的外部影響

外部宏觀環境因素在塑造抗凝血劑市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解抗凝血劑市場的競爭格局

抗凝血劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：抗凝血劑市場供應商績效評估

FPNV定位矩陣是評估抗凝血劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃抗凝血市場的成功之路

抗凝血劑市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 靜脈血栓栓塞症和心血管疾病的發生率增加
      • 增加抗凝血治療管理計劃
      • 關於抗凝血劑的新口頭陳述的接受度提高
    • 抑制因素
      • 嚴格的藥物劑量和臨床核准規定
    • 機會
      • 採用新的抗凝血療法並增加研發投入
      • 使用人工智慧和機器學習預測抗凝血控制
    • 任務
      • 與口服抗凝血劑相關的副作用和併發症
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 抗凝血藥物市場：依給藥途徑分類

  • 介紹
  • 注射抗凝血劑
  • 口服抗凝血劑

第7章 抗凝血劑市場：依抗凝血劑分類

  • 介紹
  • 貝曲西班
  • Dabigatran
  • 艾多沙班或利伐沙班
  • 埃利奎斯

第8章抗凝血劑市場：依藥物類別

  • 介紹
  • DTIs
  • XA因子抑制劑
  • 肝素
  • 維生素K拮抗劑

第9章抗凝血劑市場：依應用分類

  • 介紹
  • 心房顫動和心臟病發作
  • 深層靜脈栓塞症
  • 肺動脈栓塞
  • 中風

第10章美洲抗凝血藥市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太抗凝血市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲抗凝血市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Akebia Therapeutics, Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Athenex, Inc.
  • Bayer AG
  • CH Boehringer Sohn AG & Ko. KG
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • LEO Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4358BACA80B8

The Anticoagulants Market was valued at USD 40.20 billion in 2023, expected to reach USD 44.24 billion in 2024, and is projected to grow at a CAGR of 10.14%, to USD 79.07 billion by 2030.

Anticoagulants are a class of drugs that prevent blood clot formation, which could lead to conditions such as stroke, heart attack, and deep vein thrombosis. The scope of anticoagulants spans across pharmaceuticals, biotechnology, and healthcare sectors as they are crucial in managing and preventing thrombotic disorders. The necessity of these drugs arises due to the increasing prevalence of cardiovascular diseases and the growing geriatric population, who are more prone to such conditions. The application of anticoagulants extends to hospitals, clinics, and homecare settings, where they are used in both therapeutic and preventive regimens. The end-use scope predominantly involves healthcare providers, whereas research institutions and pharmaceutical manufacturers are crucial stakeholders in the development and distribution. Key growth factors include advancements in drug delivery systems, increasing awareness about thrombotic conditions, and the adoption of novel oral anticoagulants (NOACs) which offer an alternative to traditional therapies like warfarin. This market also presents lucrative opportunities, propelled by emerging markets in Asia-Pacific and technological innovations like target-specific anticoagulants.

KEY MARKET STATISTICS
Base Year [2023] USD 40.20 billion
Estimated Year [2024] USD 44.24 billion
Forecast Year [2030] USD 79.07 billion
CAGR (%) 10.14%

However, market growth faces challenges like the high cost of NOACs, stringent regulatory frameworks, and the risk of bleeding complications, which necessitate careful patient monitoring. The development of antidotes remains a critical limitation, affecting the widespread adoption of NOACs. Innovation and research are being directed toward the creation of safer and more effective anticoagulants with fewer side effects. Personalization of drug therapy using pharmacogenetic insights represents a promising frontier for business growth. The nature of the market is increasingly competitive, with significant investments in R&D from leading pharmaceutical companies. Consequently, the use of real-world data and artificial intelligence to improve patient outcomes presents an exciting area for future exploration, ultimately aiming to refine the therapeutic index of anticoagulants and mitigate their challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticoagulants Market

The Anticoagulants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of venous thromboembolism and cardiovascular disorders
    • Rising number of anticoagulation stewardship programs
    • Increasing acceptance of novel oral anticoagulants
  • Market Restraints
    • Stringent regulations related to drug dosage and clinical approvals
  • Market Opportunities
    • Introduction of novel anticoagulation therapeutics and increasing R&D investments
    • Use of AI and ML to predict anticoagulation control
  • Market Challenges
    • Side-effects and complications associated with the usage of oral anticoagulants

Porter's Five Forces: A Strategic Tool for Navigating the Anticoagulants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticoagulants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticoagulants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticoagulants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticoagulants Market

A detailed market share analysis in the Anticoagulants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticoagulants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticoagulants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticoagulants Market

A strategic analysis of the Anticoagulants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Injectable Anticoagulants and Oral Anticoagulants.
  • Based on Anticoagulant Drug, market is studied across Betrixaban, Dabigatran, Edoxaban or Rivaroxaban, and Eliquis.
  • Based on Drug Class, market is studied across DTIs, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.
  • Based on Application, market is studied across Atrial fibrillation & Heart Attack, Deep Vein Thrombosis, Pulmonary Embolism, and Stroke.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
      • 5.1.1.2. Rising number of anticoagulation stewardship programs
      • 5.1.1.3. Increasing acceptance of novel oral anticoagulants
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
      • 5.1.3.2. Use of AI and ML to predict anticoagulation control
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anticoagulants Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Injectable Anticoagulants
  • 6.3. Oral Anticoagulants

7. Anticoagulants Market, by Anticoagulant Drug

  • 7.1. Introduction
  • 7.2. Betrixaban
  • 7.3. Dabigatran
  • 7.4. Edoxaban or Rivaroxaban
  • 7.5. Eliquis

8. Anticoagulants Market, by Drug Class

  • 8.1. Introduction
  • 8.2. DTIs
  • 8.3. Factor XA Inhibitors
  • 8.4. Heparin
  • 8.5. Vitamin K Antagonists

9. Anticoagulants Market, by Application

  • 9.1. Introduction
  • 9.2. Atrial fibrillation & Heart Attack
  • 9.3. Deep Vein Thrombosis
  • 9.4. Pulmonary Embolism
  • 9.5. Stroke

10. Americas Anticoagulants Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anticoagulants Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anticoagulants Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akebia Therapeutics, Inc.
  • 2. Aspen Pharmacare Holdings Limited
  • 3. AstraZeneca PLC
  • 4. Athenex, Inc.
  • 5. Bayer AG
  • 6. C.H. Boehringer Sohn AG & Ko. KG
  • 7. Eisai Co., Ltd.
  • 8. Eli Lilly and Company
  • 9. Johnson & Johnson
  • 10. LEO Pharma A/S
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ANTICOAGULANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICOAGULANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICOAGULANTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY EDOXABAN OR RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ELIQUIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION & HEART ATTACK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTICOAGULANTS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023